Introduction: The most active single agents in NSCLC are Mitomycin-C, Ifosfamide, Vindesine and cis-Platinum. DDPContaining combinations showed a remission rate of about 40 ~ (own results) ~ith high rate of toxicity. To improve results we have to look For new drug combinations with tolerable toxicity. This ~ss the rationale for a phsse-IItrial to determine the effectiveness and toxicity of the triple-drug regimen with Mitomycin-C, Ifosfamide and Vindesine. Patients and methods: Since 5/1984 55 patients with inoperable NSCLC were entered in the study until 4/1985. 50 patients are evaluable for response and median survival time, 46 male, 9 female. Median age 60,5 years. Performance-Status more than 70 % in all patlents. 58/55 patients had extensive disease. Histology: 40 squamous cell, 9 large cell, 6 adeno carcinomas. Prior chemotherapy: 9 (DDPIVP-16). (CHOP) entered a study_using the following therapy: etopQside 100mg/m z iv day I -3, ifosfami~e'1,0 g/m z iv day I -5, methotrexate 30 mg/m-iv day 3 and bleomycin 10 mg iv day 7 and 14. For prophylaxis of cystitis, uromitexan was given together with ifosfamide. Cycles were repeated in a three weeks' interval. Preliminary results of this ongoing study are as follows: 8 patients (44%) achieved a complete remission, with a median follow up of 12 months, three of these patients relapsed 6, 6, and 18 months after start of salvage therapy. 3 patients showed a partial remission. 7 patients had only a minor or no response. Median survival from start of therapy is 16 months (projected) for all patients. It is not yet reached for responders and only 4 months for non-responders.
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SALVAGE THERAPY WITH ETOPOSIDE,IFOSFAMIDE,METHO-TREXATE AND BLEOMYCIN IN NON-HODGKIN'S LYMPHOMAS B.Steinke, F.W. Busch, M.Heim, H. Arnold
18 patients with NHL (centrocytic 2, centroblastic-centrocytic 2, centroblastic 8, immunoblastic 3, high malignant, not further defined 3) resistant to first-line treatment (CHOP) entered a study_using the following therapy: etopQside 100mg/m z iv day I -3, ifosfami~e'1,0 g/m z iv day I -5, methotrexate 30 mg/m-iv day 3 and bleomycin 10 mg iv day 7 and 14. For prophylaxis of cystitis, uromitexan was given together with ifosfamide. Cycles were repeated in a three weeks' interval. Preliminary results of this ongoing study are as follows: 8 patients (44%) achieved a complete remission, with a median follow up of 12 months, three of these patients relapsed 6, 6, and 18 months after start of salvage therapy. 3 patients showed a partial remission. 7 patients had only a minor or no response. Median survival from start of therapy is 16 months (projected) for all patients. It is not yet reached for responders and only 4 months for non-responders.
Toxicity of treatment was usually mild. In 14 % of 50 cycles analysed so far, leucocytes fell below 2OOO~ul. In 6 % thrombocytes dropped to less than 75000~ui. 4 series were complicated by fever which Was treated by antibiotic therapy. Stomatitis was mild and seen only in 2 series. 3 patients had skin alterations similar to scleredermia.
In these cases bleomycin was stopped and the skin alterations regressed. These results show, that the combination of ifosfamide, etoposide, methotrexate, and bleomycin is an effective treatment in NEL resistant to first-line therapy. Updated data will be presented at the meeting. . In 3 pts with CNS involvement, i/3 of each MTX dose (=i0 mg/m 2 ) was given i.th. In i0 pts, Bleomycin (15 mg s.c., Days 1,5,12) was given additionally and in a further I0 pts, higher dosages of MTX (50-100 mg/m 2 , Days i, 5) was applied together with Leucovorin rescue. Treatment was repeated every 3-4 weeks. The overall response rate was 83% with a complete remission (CR) rate of 30% and a partial remission (PR) rate of 53%. 3 out of [9 pts with refractory lymphomas and 6 out of 10 with relapsing diseases achieved CR. The rate of PRs was 12/19 and 4/10 respectively, i CR and 8 PRs were obtained in the Ii pts with HD (8 refractory, 3 relapsed). Of the 19 pts with NHL (I0 refractory, 9 relapsed), 8 pts responded with CR and 8 pts with PR. The duration of CRs was 2-11+ and that of PRs 3-10+ months. Major toxicities observed in a total number of 95 therapy courses were stomatitis (6%) and septicemia (5%) occuring mainly in pts with i.th. MTX. No therapy related death was observed. On the basis of these results, VIM(B) combination appears to be an effective and well tolerated regimen in pts with refractory or relapsed lymphomas. Thus, it appears to be reasonable to evaluate the efficacy of this drug combination in relation to the primary therapy of these diseases. po. d 1-14, repeated d 28. After I-3 (median:2) IBEP-chemotherapy courses in 3 pts a CR and in 4 pts a PR was achieved with a median remission duration of 8 + months; in the remaining 3 pts no change was observed. If future studies will confirm the encouraging result of this pilot study, the IBEP-combination chemotherapy may represent not only an effective salvage therapy particularly of CHOP-resistant NHL, but also a potential improvement of the initial chemotherapy of NHL by alternating noncross-resistant chemotherapy combinations. Abtlg. for H~matologie u. Onkologie, Augusta-Kranken-Anstalt, Bergstr. 26, 463o Bochum
